Ohio’s Mass Vaccination Clinic in Cleveland to Offer Johnson & Johnson Vaccine Next Week

 

(COLUMBUS, Ohio)—Ohio Governor Mike DeWine announced today that Ohio’s state-federal mass vaccination clinic in downtown Cleveland will offer the Johnson & Johnson vaccine next week. Anyone age 18 or older may receive the single-dose Johnson & Johnson vaccine from Tuesday, May 11, through Monday, May 17.

The clinic, located at Cleveland State University’s Wolstein Center at 2000 Prospect Avenue, accepts walk-ins from 8 a.m. to 7 p.m. Appointments can also be booked online at gettheshot.coronavirus.ohio.gov or by calling 833-4-ASK-ODH.

The mass vaccination clinic, which is operating in partnership between the state of Ohio, Federal Emergency Management Agency, City of Cleveland, Cuyahoga County, and Cleveland State University, launched in mid-March. In its first six weeks of operations, more than 237,000 first and second doses of the Pfizer vaccine were administered.

The clinic will continue offering first doses of the Pfizer vaccine to anyone age 16 or older through Monday, May 10. Second doses of the Pfizer vaccine will be administered beginning on Tuesday, May 18, for those who received their first doses of vaccine at the Wolstein Center in late April and early May.

Current Wolstein Center Mass Vaccination Clinic Timeline:

  • Tuesday, March 16 – Monday, April 5: Pfizer first doses
  • Tuesday, April 6 – Monday, April 26: Pfizer second doses
  • Tuesday, April 27 – Monday, May 10: Pfizer first doses
  • Tuesday, May 11 – Monday, May 17: Johnson & Johnson single doses
  • Tuesday, May 18 – Monday, May 31: Pfizer second doses

The clinic may extend beyond May 31 if demand for vaccine in a mass vaccination setting warrants that the clinic continue. There are currently more than 1,100 other local area providers offering vaccines across the state.

Administration of the Johnson & Johnson vaccine was paused in Ohio last month as the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization conducted a thorough review of extremely rare blood-clotting events reported to the Vaccine Adverse Event Reporting System. The CDC and Food and Drug Administration (FDA) allowed use of the Johnson & Johnson vaccine to resume on April 23 after comprehensive analysis found that the benefits of the Johnson & Johnson vaccine outweigh the risks. Providers in Ohio were permitted to immediately resume administering the Johnson & Johnson vaccine provided they continue to follow all guidance by the CDC and FDA.